Targeted combo therapy tested for Tough-to-Treat uterine cancer
Disease control
Ongoing
This study is testing whether a combination of two drugs, alpelisib and fulvestrant, can help control advanced endometrial cancer that has a specific genetic mutation (PIK3CA) and responds to estrogen. It is for people whose cancer has returned or spread and is not likely curable…
Phase: PHASE2 • Sponsor: GOG Foundation • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC